腾讯网2 天
关于地舒单抗的5个常见患者提问
地舒单抗地舒单抗在临床用于骨质疏松、骨巨细胞瘤、多发性骨髓瘤和实体肿瘤骨转移的治疗。这是目前唯一上市的RANKL抑制剂。它可以与RANK蛋白竞争性结合RANKL蛋白，从而抑制RANKL-RANK-OPG信号通路介导的破骨细胞分化与激活，降低破骨活动， ...
JD Supra5 天
Regulatory Updates on Samsung’s Denosumab Biosimilars
On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...
Managed Healthcare Executive6 天
FDA Approves Second Biosimilars for Prolia/Xgeva
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.
Trump’s record-breaking start rattles Washington, rankles rivals, but earns raves from voters
President Trump, in a burst of presidential action unmatched in modern U.S. history, has loosed a flurry of executive orders ...